Ovarian Cancer

Health written question – answered on 5th September 2013.

Alert me about debates like this

Photo of Sharon Hodgson Sharon Hodgson Shadow Minister (Education)

To ask the Secretary of State for Health whether ovarian cancer drugs previously appraised but not recommended by the National Institute for Health and Care Excellence will be re-assessed under value-based pricing.

Photo of Norman Lamb Norman Lamb The Minister of State, Department of Health

Value-based pricing will focus primarily on new medicines. It is possible that a. small number of existing drugs, such as some cancer drugs previously considered but not recommended by the National Institute for Health and Care Excellence (NICE), could be assessed under value-based pricing. However, it is not our intention under value-based pricing to routinely reassess treatments already appraised by NICE.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.